Hypertension (High Blood Pressure) News and Research

RSS

Hypertension (or high blood pressure) is a condition where the pressure of the blood flowing through the arteries of the body is higher than it should be. Much like the pressure of the air in a tire, if the pressure of the blood is too high it can damage the arteries and organs of the body. Just like the tire, if the pressure suddenly becomes very high, catastrophic events can happen. Similarly, if the pressure remains somewhat elevated for a long enough period of time, premature wear and failure can occur.

Hypertension has its worst effects on the heart, kidneys, eyes, and brain. High blood pressure is a risk factor for heart attack, stroke, kidney failure, hemorrhages of the retina of the eye, and generalized atherosclerosis (hardening of the arteries all over the body).

Raise awareness about psoriasis: National Psoriasis Foundation's call to psoriasis affected Americans

Today is World Psoriasis Day and the National Psoriasis Foundation is asking all Americans affected by psoriasis and psoriatic arthritis to raise awareness about these diseases by going to www.psoriasis.org/wpd and taking action.

29 Oct 2009

CHS, BPC and CHEP integrated into one hypertension entity

The Heart and Stroke Foundation of Canada today welcomed the integration of the Canadian Hypertension Society (CHS), Blood Pressure Canada (BPC), and the Canadian Hypertension Education Program (CHEP) into one hypertension entity.

29 Oct 2009

Impact of wellness programs on pharmaceutical, diagnostic and device markets

MarketResearch.com has announced the addition of Kalorama Information's new report, "The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets," to their collection of Healthcare market reports.

29 Oct 2009

Sixth round of recipients of Pfizer Cardiovascular Research Awards Program announced

Pfizer Canada is pleased to announce the sixth round of recipients of the Pfizer Cardiovascular Research Awards Program. The program, first launched in October 2005, was developed to fund and support cardiovascular research in Canada.

29 Oct 2009

New CCS guidelines and position papers for physicians and nurse practitioners

Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.

28 Oct 2009

New clinical uses for old hypertension drug leads to several patents

University of South Florida neuroscientist R. Douglas Shytle's discovery of successful new clinical uses for mecamylamine, a drug once used to treat hypertension, has led to several issued patents on mecamylamine and related compounds. Earlier this month, Shytle, associate professor and research scientist at the USF Center of Excellence for Aging and Brain Repair and the USF Silver Child Development Center, received the university's 2009 "Excellence in Innovation" award.

28 Oct 2009

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride levels and other metabolic measures, according to a study in the October 28 issue of JAMA.

28 Oct 2009

Internet-based diet and exercise program shows promise in lowering healthcare costs

Researchers from Boston University School of Medicine (BUSM) and Boston University School of Public Health (BUSPH) have shown that an employer-sponsored, internet-based diet and exercise program shows promise as a low-cost benefit to lower healthcare costs for those at higher risk for above-average costs and healthcare utilization such as cardiac, hyperlipidemia, hypertension or diabetes patients.

28 Oct 2009

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

A first-time finding of intraocular pressure increases in patients with no personal or family history of glaucoma following anti-VEGF treatment for wet age-related macular degeneration (AMD), and a report on a simple, low-cost method that could revolutionize vision screening and treatment in developing countries, are highlights of today's Scientific Program of the 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and the Pan-American Association of Ophthalmology (PAAO).

27 Oct 2009

Dexmedetomidine can reduce pain when removing a tube from the airway of critically ill patients

A study presented at this year's American Society of Anesthesiologists (ASA) Annual Meeting demonstrated that the use of the sedative Dexmedetomidine was safe and reduced the amount of time for the extubation process, or the process of removing a tube from the airway of critically ill patients.

26 Oct 2009

DaVita to demonstrate clinical outcomes, patient care and nutrition through 43 abstracts

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), in conjunction with DaVita Clinical Research®, today announced that company representatives will deliver 43 abstracts—40 posters and three oral presentations—at this year’s American Society of Nephrology’s (ASN) Renal Week to be held in San Diego, Calif., from Oct. 27 – Nov. 1, 2009.

24 Oct 2009

Learn to recognise stroke symptoms and take action: World Stroke Organization

The theme of this year's World Stroke Day on 29th October is "What can I do?". As the World Stroke Organization says, everyone can do something: learn to recognise symptoms and take action, learn to recognise the risk factors and take action.

24 Oct 2009

Updated data on XL184 study in patients with glioblastoma multiforme presented

Exelixis, Inc. and Bristol-Myers Squibb Company today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

24 Oct 2009

Vasamed partners with BBHOP for peripheral arterial disease research

On Saturday, November 7, 2009 Vasamed Inc., provider of diagnostic technologies that detect peripheral arterial disease in patients with diabetes, will partner with the Black Barbershop Health Outreach Program (BBHOP) in its mission to help African Americans identify the connection between peripheral arterial disease (PAD), diabetes, obesity and hypertension through early detection and referral to appropriate medical resources.

23 Oct 2009

Accredo Health Group announces a 10-year renewal of its headquarters with Memphis

Accredo Health Group Inc. announced a 10-year renewal of its 240,000-square-foot headquarters at Century Center, positioning the nation's largest specialty pharmacy and a major fixture of Memphis' health care industry for future growth. The General Investment & Development Companies and Accredo agreed to renew all leases for Accredo's five-building campus, effective January 1, 2010.

22 Oct 2009

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive results from a Phase 2a study of its Rho-kinase (ROCK) inhibitor, AR-12286. The study evaluated the safety, tolerability and efficacy of three different doses of AR-12286 in 88 patients with primary open angle glaucoma or ocular hypertension.

22 Oct 2009

NicOx reports financial results for the first nine months of 2009

NicOx S.A. today reported financial results for the nine months ended September 30, 2009.

22 Oct 2009

CWRU establishes collaborative research center to address common health issues in urban neighborhoods

Case Western Reserve University (CWRU) School of Medicine proudly announces the establishment of the CWRU Prevention Research Center for Healthy Neighborhoods (PRCHN), a collaborative research center to address common health issues faced in disadvantaged urban neighborhoods in and around Greater Cleveland.

22 Oct 2009

New results from ADVANCE provide important insights to reduce diabetes complications

New results from ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial ever performed in patients with type 2 diabetes worldwide, provide important insights into the therapeutic strategy to adopt for efficient and safe blood glucose control aimed at the reduction of severe diabetes complications.

21 Oct 2009

APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Chlorothiazide Sodium for Injection, USP. APP expects to launch Chlorothiazide Sodium for Injection, USP in the fourth quarter of 2009.

21 Oct 2009

Hypertension (High Blood Pressure) News and Research

Further Reading

Raise awareness about psoriasis: National Psoriasis Foundation's call to psoriasis affected Americans

CHS, BPC and CHEP integrated into one hypertension entity

Impact of wellness programs on pharmaceutical, diagnostic and device markets

Sixth round of recipients of Pfizer Cardiovascular Research Awards Program announced

New CCS guidelines and position papers for physicians and nurse practitioners

New clinical uses for old hypertension drug leads to several patents

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Internet-based diet and exercise program shows promise in lowering healthcare costs

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

Dexmedetomidine can reduce pain when removing a tube from the airway of critically ill patients

DaVita to demonstrate clinical outcomes, patient care and nutrition through 43 abstracts

Learn to recognise stroke symptoms and take action: World Stroke Organization

Updated data on XL184 study in patients with glioblastoma multiforme presented

Vasamed partners with BBHOP for peripheral arterial disease research

Accredo Health Group announces a 10-year renewal of its headquarters with Memphis

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

NicOx reports financial results for the first nine months of 2009

CWRU establishes collaborative research center to address common health issues in urban neighborhoods

New results from ADVANCE provide important insights to reduce diabetes complications

APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News